MYLAN-ABACAVIR/LAMIVUDINE 300 MG
LAMIVUDINE : 300 MG ABACAVIR (ABACAVIR SULFATE) : 600 MG · DIN 02450682 · MYLAN PHARMACEUTICALS ULC
Health Canada status: MARKETED
What is MYLAN-ABACAVIR/LAMIVUDINE?
MYLAN-ABACAVIR/LAMIVUDINE 300 MG contains LAMIVUDINE : 300 MG ABACAVIR (ABACAVIR SULFATE) : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 02450682, held by MYLAN PHARMACEUTICALS ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 29-Mar-2016. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02450682 |
|---|---|
| Brand name | MYLAN-ABACAVIR/LAMIVUDINE |
| Generic / active ingredient | LAMIVUDINE : 300 MG ABACAVIR (ABACAVIR SULFATE) : 600 MG |
| Manufacturer | MYLAN PHARMACEUTICALS ULC |
| Strength | 300 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J05AR02 LAMIVUDINE AND ABACAVIR |
| AHFS class | 08:18.08.20 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 29-Mar-2016 |
| Original market date | 2016-03-29 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J05AR02 LAMIVUDINE AND ABACAVIR. 4 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AURO-ABACAVIR/LAMIVUDINE | 600 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02454513 |
| JAMP ABACAVIR / LAMIVUDINE | 600 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02497654 |
| TEVA-ABACAVIR/LAMIVUDINE | 300 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02416662 |
| APO-ABACAVIR-LAMIVUDINE | 300 MG | TABLET | APOTEX INC | DORMANT | DIN 02399539 |
| APO-ABACAVIR-LAMIVUDINE TABLETS | 300 MG | TABLET | APOTEX INC | APPROVED | DIN 02518287 |
| KIVEXA | 300 MG | TABLET | VIIV HEALTHCARE ULC | CANCELLED POST MARKET | DIN 02269341 |
| MINT-ABACAVIR/LAMIVUDINE | 300 MG | TABLET | MINT PHARMACEUTICALS INC | APPROVED | DIN 02497808 |
| PMS-ABACAVIR-LAMIVUDINE | 300 MG | TABLET | PHARMASCIENCE INC | DORMANT | DIN 02458381 |
Who else supplies LAMIVUDINE AND ABACAVIR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. LAMIVUDINE AND ABACAVIR appears in 32 registered pack listings across 6 markets, published on 6 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.